Home
Storia in 2 fonti
Merck splits operations to separate oncology from non-cancer drugs
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda
- ·
ft.com
Gilead to buy cancer drug developer Arcellx for up to $7.8bn
Deal comes as pharmaceutical groups rush to acquire smaller biotech firms with proven drug pipelines
- ·
cnbc.com
Merck to create separate cancer business as Keytruda patent loss looms
Merck said on Monday it will split its human-health business into two divisions, separating its cancer franchise from its non-oncology medicines.
- ·
Merck splits operations to separate oncology from non-cancer drugs
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda